Every Form 4 that EVOMMUNE INC (EVMN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EVMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVMN filings page.
Evommune, Inc. Chief Financial Officer Kyle Carver purchased 1,000 shares of common stock in an open-market transaction at $13.26 per share, bringing his direct holdings to 60,335 shares. A prior sale of 1,000 shares at $23.42 on May 28, 2026 triggered Section 16(b) short-swing profit rules, and he agreed to pay $10,160 of profit to Evommune.
Evommune, Inc. director Arthur S. Kirsch reported an indirect open-market purchase of 10,000 shares of common stock at a weighted average price of $13.30 per share. The shares are held by a family trust for which he is a trustee, and he disclaims beneficial ownership except for his proportionate pecuniary interest.
Evommune, Inc. Chief of Development Operations Janice Suzann Drew exercised stock options and sold shares in a planned trade. On June 22, 2026, she exercised options to acquire a total of 20,000 shares of common stock at exercise prices of $2.99 and $3.84 per share, then sold 20,000 shares in an open-market transaction at a weighted average price of $22.63 per share.
The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2026, indicating they were scheduled in advance. Footnotes also describe a standard multi-year vesting schedule for the underlying employee stock options.
Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel executed an option exercise and related share sale in Evommune (EVMN) stock. On June 22, 2026, he exercised 1,488 employee stock options at $3.84 per share and sold 1,488 common shares in an open-market transaction at $22.50 per share. Following these transactions, he directly holds 46,403 shares of common stock and 27,842 employee stock options, which are scheduled to vest over time and expire on May 11, 2033. The filing notes that the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, indicating the timing was set in advance.
Evommune, Inc. director and President & CEO Luis C. Pena reported an open-market sale of 7,438 shares of common stock on June 22, 2026 at a weighted average price of $22.71 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 2, 2026, indicating they were scheduled in advance. Following this sale, Pena directly holds 630,458 shares of Evommune common stock, so the sale represents only a small portion of his overall stake.
Evommune, Inc. director Benjamin F. McGraw III received a grant of stock options covering 15,673 shares of common stock. The options have an exercise price of $19.82 per share and expire on June 1, 2036.
According to the footnote, these options vest at the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, provided he remains in continuous service through that date. Following this grant, he holds options to acquire 15,673 shares directly. This is a routine compensation-related award, not an open-market share purchase or sale.
Evommune, Inc. director Arthur S. Kirsch received a grant of stock options covering 15,673 shares of common stock. The options have an exercise price of $19.82 per share and expire on June 1, 2036. Following this grant, he holds options on 15,673 shares directly.
The award vests at the earlier of the first anniversary of the grant date or Evommune’s next annual meeting of stockholders, as long as Kirsch continues to serve through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Evommune director David E. Cohen reported both stock sales and a new option grant. He sold a total of 6,056 shares of common stock in two open-market transactions at weighted average prices of $20.21 and $21.38, executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026.
On the same date, he received a grant of stock options covering 15,673 shares of common stock with an exercise price of $19.82 per share, expiring on June 1, 2036. These options vest at the earlier of the first anniversary of the grant date or Evommune’s next annual meeting of stockholders, as long as he continues to serve through that date.
Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel reported an exercise-and-sale transaction in company stock. He exercised employee stock options to acquire 13,512 shares of common stock at a price of $3.84 per share, then sold 16,687 shares of common stock at a weighted average price of $22.74 per share in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026. Following these transactions, he directly holds 46,403 shares of common stock and 29,330 employee stock options that remain outstanding and exercisable into common stock.
Evommune, Inc. President & CEO Luis C. Pena reported an open-market sale of common stock. On June 1, 2026, he sold 16,787 shares of Evommune common stock at a weighted average price of $22.74 per share in multiple transactions. These trades were made pursuant to a pre-arranged Rule 10b5-1 trading plan. After the sale, Pena directly holds 637,896 shares of Evommune common stock.
Evommune, Inc. executive Gregory S. Moss reported an exercise-and-sale transaction in company stock. He exercised employee stock options for 14,223 shares of common stock at an exercise price of $1.71 per share and sold 14,223 shares in an open-market transaction at a weighted average price of $22.83 per share. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 26, 2026, indicating they were scheduled in advance. Following the transactions, Moss holds 60,835 shares of Evommune common stock directly and an additional 3,175 shares indirectly through a family trust, and he continues to hold 47,845 employee stock options with a $1.71 exercise price expiring in 2034.
Evommune, Inc. Chief Financial Officer Kyle Carver reported an option exercise and related share sale. On May 28, he exercised options to acquire 15,000 shares of common stock at $2.99 per share and sold 18,175 shares of common stock in open-market transactions at a weighted average price of $22.84 per share.
The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 26, 2026, indicating they were scheduled in advance. Following the sale, Carver directly holds 59,335 shares of Evommune common stock.
Patel Jeegar Pravinkumar reported acquisition or exercise transactions in this Form 4 filing.
Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel received an employee stock option grant for 69,315 shares of common stock. The option has a strike price of $26.77 per share and expires on April 15, 2036, with no cash paid for the grant itself.
According to the vesting terms, one quarter of the option vests on the first anniversary of the grant date. The remaining three quarters vest in 36 equal monthly installments, contingent on Patel’s continuous service with the company. After this award, he holds 69,315 derivative securities directly.
Evommune, Inc. reported that Chief of Development Operations Janice Suzann Drew received an employee stock option grant covering 73,892 shares of common stock. The options carry an exercise price of $26.77 per share and expire on April 15, 2036.
According to the vesting terms, one fourth of the options will vest on the first anniversary of the grant date, with the remaining options vesting in 36 equal monthly installments thereafter, contingent on continued service. Following this grant, the reporting person holds 73,892 stock options directly.
Evommune, Inc. reported that Chief Medical Officer Eugene Bauer received an award of employee stock options covering 51,117 shares of common stock. The options have an exercise price of $26.77 per share and expire on April 15, 2036.
One quarter of the options vest on the first anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments, contingent on his continued service. Following this grant, Bauer holds 51,117 derivative securities directly.
Evommune, Inc. reported that Chief Financial Officer Kyle Carver received an employee stock option grant. The award covers 98,946 shares of common stock at an exercise price of $26.77 per share and expires on April 15, 2036.
According to the vesting terms, one fourth of the option vests on the first anniversary of the grant, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to his continuous service. Following this grant, he holds 98,946 derivative securities directly.
Evommune, Inc. reported that Chief Business & Legal Officer Gregory S. Moss received an option grant for 115,279 shares of common stock at an exercise price of $26.77 per share. The options expire on April 15, 2036 and represent his entire reported option position from this grant.
According to the vesting terms, one fourth of the shares will vest on the first anniversary of the grant date, and the remaining shares will vest in 36 equal monthly installments thereafter, subject to his continuous service with the company.
Evommune, Inc. President & CEO Luis C. Pena received a grant of employee stock options covering 291,420 shares of common stock. The options have an exercise price of $26.7700 per share and expire on April 15, 2036. Following this grant, he holds 291,420 derivative securities related to this award.
According to the vesting schedule, one quarter of the options vests on the first anniversary of the grant date, with the remaining options vesting in 36 equal monthly installments, subject to his continuous service. This is a compensation-related award rather than an open-market purchase or sale.
Evommune, Inc. director and 10% owner LSP 7 Cooperative UA, through its affiliated entity, acquired 358,680 shares of Common Stock as a grant or award on February 17, 2026 at $27.88 per share. Following this transaction, LSP 7 reported holding 5,288,313 shares indirectly. The shares are held of record by LSP 7 Cooperatief UA, with LSP 7 Management B.V. as sole director; its managing directors may be deemed to share beneficial ownership but each disclaims beneficial ownership of these shares.
Evommune, Inc. reported an insider-related equity award involving an affiliated investment entity. On February 17, 2026, LSP 7 Cooperatief U.A., an entity associated with director and 10% owner Felice Isabel Verduyn-van Weegen, acquired 358,680 shares of common stock at $27.88 per share through a grant or award. Following this transaction, the entity held 5,288,313 common shares indirectly attributed to the reporting person, who disclaims beneficial ownership except to the extent of any pecuniary interest.
RA CAPITAL MANAGEMENT, L.P. reported acquisition or exercise transactions in a Form 4 filing for EVMN. The filing lists transactions totaling 35,868 shares at a weighted average price of $27.88 per share. Following the reported transactions, holdings were 2,710,293 shares.
Evommune, Inc. insider and 10% owner reports a share purchase. A reporting person who is both a director and 10% owner of Evommune, Inc. (EVMN) disclosed buying 1,000 shares of common stock on 12/19/2025 at a price of $17.35 per share through a family trust.
After this transaction, 4,026 shares of common stock are reported as indirectly owned through the family trust. Additional indirect holdings are reported as 1,441,032 shares through NFLS Delta III Limited, 1,632,441 shares through Pivotal bioVenture Partners Fund I, L.P., and 294,502 shares through Pivotal bioVenture Partners Fund II, L.P. In each case, the reporting person disclaims beneficial ownership beyond their proportionate pecuniary interest.
Evommune, Inc. reported an equity award to one of its senior leaders. On 12/08/2025, a reporting person who serves as both a director and Chief Medical Officer received an employee stock option to buy 100,000 shares of Evommune common stock at an exercise price of $18.44 per share. The option expires on 12/08/2035.
One fourth of the option shares will vest on December 8, 2026, and the remaining shares will vest in 36 equal monthly installments after that date, as long as the reporting person continues to provide service. After this grant, the reporting person beneficially owns 100,000 derivative securities directly.
Evommune, Inc. President and CEO, who is also a director, reported an automatic share withholding related to equity compensation. On 12/09/2025, 28,138 shares of Evommune common stock were disposed of at a reported price of $17.84 per share. The filing explains that these shares were withheld to cover the reporting person's tax withholding obligations upon the settlement of restricted stock units, rather than an open-market sale. After this tax withholding event, the reporting person beneficially owns 654,683 shares of Evommune common stock in direct ownership.
Evommune, Inc. reported an insider equity transaction by its Chief Scientific Officer, who is an officer of the company and files individually. On 12/09/2025, the officer had 7,513 shares of common stock withheld, coded as an "F" transaction, at a price of $17.84 per share. According to the explanation, these shares were withheld to cover the officer’s tax obligations arising from the settlement of restricted stock units, a common administrative step when stock awards vest.
After this tax withholding event, the officer beneficially owned 49,578 shares of Evommune common stock in direct ownership. The filing indicates this was not part of a trading plan under Rule 10b5-1, and does not involve any derivative securities such as options or warrants.
Evommune, Inc. executive Gregory S. Moss, the company’s Chief Business & Legal Officer, reported an insider transaction involving company stock. On 12/09/2025, 13,624 shares of Evommune common stock were withheld at a price of $17.84 per share to cover his tax withholding obligations tied to the settlement of restricted stock units. After this transaction, he directly beneficially owned 60,835 shares of common stock and indirectly held 3,175 additional shares through a family trust in which he serves as trustee.
Evommune, Inc. executive vice president of operations reported an insider equity transaction. On 12/09/2025, the officer had 5,074 shares of Evommune common stock withheld, coded as an "F" transaction, at a price of $17.84 per share. The filing explains these shares were withheld to satisfy tax withholding obligations tied to the settlement of restricted stock units, rather than being an open-market sale. After this tax-related transaction, the reporting person beneficially owned 67,794 shares of Evommune common stock directly.
Evommune, Inc. reported an insider equity transaction by its Chief Financial Officer on a Form 4. On 12/09/2025, 13,290 shares of common stock were withheld at a price of $17.84 per share to cover the officer’s tax obligations tied to the settlement of restricted stock units. After this tax withholding event, the CFO directly beneficially owned 62,510 shares of Evommune common stock.
Evommune, Inc. reported an insider equity transaction by a director and Chief Medical Officer. On 12/09/2025, the insider had 1,478 shares of common stock withheld at a price of $17.84 per share to cover tax withholding obligations tied to the settlement of restricted stock units. After this tax-related withholding, the insider beneficially owns 270,818 shares of Evommune common stock in direct ownership.
Evommune, Inc. (EVMN) reported insider ownership changes tied to its initial public offering. RA Capital–affiliated entities converted Series C Preferred Stock into Common Stock immediately prior to the IPO and also bought additional shares in the offering.
The Fund and RA Capital Nexus Fund III converted preferred stock into 1,517,329 and 691,441 shares of Common Stock, respectively, and then purchased 1,157,096 and 92,904 additional Common shares at $16 per share. These holdings are reported as indirectly owned, with RA Capital Management, L.P., its general partner, and related individuals disclaiming beneficial ownership beyond their pecuniary interests. The reporting persons are identified as both a director affiliate and 10% owner of Evommune.
Evommune, Inc. insider LSP 7 Management B.V., as director of LSP 7 Cooperatief U.A., reported multiple equity transactions dated 11/07/2025. All outstanding shares of Series A, Series B, and Series C preferred stock automatically converted into common stock immediately before Evommune’s initial public offering, for no additional consideration, at fixed ratios for each series. Following these conversions, the reporting person bought an additional 1,562,500 shares of common stock at $16 per share. After the reported transactions, LSP 7 Cooperatief U.A. directly held 4,929,633 shares of Evommune common stock.